Literature DB >> 32107952

Enriched environment ameliorates dexamethasone effects on emotional reactivity and metabolic parameters in mice.

Eslen Delanogare1, Raul Marin de Souza1, Giovana Karoline Rosa2, Fernando Garcia Guanabara3, Alex Rafacho2, Eduardo Luiz Gasnhar Moreira1,2.   

Abstract

Convincing evidence shows that stress is associated with the development and course of psychiatric and metabolic disorders. The hypothalamic-pituitary-adrenal (HPA) axis mediates the stress response, a cascade of events that culminate in the release of glucocorticoids from the adrenal cortex. Chronic hypercortisolism typically characterizes stress-related illnesses, such as depression, anxiety, and metabolic syndrome. Considering previous studies pointing that environmental enrichment (EE) mitigates the deleterious effects of stress on neurobiological systems, we hypothesized that EE can confer resiliency against prolonged glucocorticoid administration-induced behavioral and metabolic alterations in mice. In this regard, three-month-old male Swiss mice were exposed to a four-week period of standard environment (SE) or EE. After this period, still in the respective environments, dexamethasone was administered intraperitoneally (i.p.) at a dose of 4 mg/kg, for 21 consecutive days, in order to generate the emotional-related behavioral outcomes, as previously described. It is demonstrated herein that EE prevents the dexamethasone-induced anxiety-like and passive stress-coping behaviors, as observed in the open field and tail suspension tests. Moreover, EE mitigated the hyperproteinemia and body weight loss induced by excess dexamethasone and decreased basal glucose levels. Taken together, these results support the hypothesis that EE attenuates the effects of chronic administration of synthetic glucocorticoids in mice, a strategy that may be translated to the clinical perspective.

Entities:  

Keywords:  Dexamethasone; behavior dysfunctions; environmental enrichment; metabolic dysfunctions

Mesh:

Substances:

Year:  2020        PMID: 32107952     DOI: 10.1080/10253890.2020.1735344

Source DB:  PubMed          Journal:  Stress        ISSN: 1025-3890            Impact factor:   3.493


  4 in total

1.  The prevalence and related factors of metabolic syndrome in outpatients with first-episode drug-naive major depression comorbid with anxiety.

Authors:  Yinghua Zhong; Manji Hu; Qiang Wang; Zhendong Yang; Na Zhu; Fei Wang; Xiyan Zhang; Chengfang Zhang; Jie Min; Hao Wang; Fazhan Chen; Xudong Zhao; Xiangyang Zhang
Journal:  Sci Rep       Date:  2021-02-08       Impact factor: 4.379

2.  Isorhamnetin Alleviates Airway Inflammation by Regulating the Nrf2/Keap1 Pathway in a Mouse Model of COPD.

Authors:  Yifan Xu; Jing Li; Zhiwei Lin; Weiquan Liang; Lijie Qin; Jiabin Ding; Shuqi Chen; Luqian Zhou
Journal:  Front Pharmacol       Date:  2022-03-24       Impact factor: 5.810

3.  Environmental Enrichment Reverses Maternal Sleep Deprivation-Induced Anxiety-Like Behavior and Cognitive Impairment in CD-1 Mice.

Authors:  Yue-Ming Zhang; Yun-Zhou Cheng; Ya-Tao Wang; Ru-Meng Wei; Yi-Jun Ge; Xiao-Yi Kong; Xue-Yan Li
Journal:  Front Behav Neurosci       Date:  2022-07-13       Impact factor: 3.617

4.  Chronic clomipramine treatment reverses depressogenic-like effects of a chronic treatment with dexamethasone in rats.

Authors:  Abderrahim Laaziz; Hicham El Mostafi; Aboubaker Elhessni; Tarik Touil; Hanane Doumar; Abdelhalem Mesfioui
Journal:  IBRO Neurosci Rep       Date:  2022-08-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.